179 related articles for article (PubMed ID: 38278367)
1. Anti-stromal nanotherapeutics for hepatocellular carcinoma.
Yu Z; Huang L; Guo J
J Control Release; 2024 Mar; 367():500-514. PubMed ID: 38278367
[TBL] [Abstract][Full Text] [Related]
2. Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review.
Huang Y; Wang T; Yang J; Wu X; Fan W; Chen J
Int J Nanomedicine; 2022; 17():2335-2352. PubMed ID: 35619893
[TBL] [Abstract][Full Text] [Related]
3. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.
Sas Z; Cendrowicz E; Weinhäuser I; Rygiel TP
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409139
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma.
Yin Z; Dong C; Jiang K; Xu Z; Li R; Guo K; Shao S; Wang L
J Hematol Oncol; 2019 Sep; 12(1):101. PubMed ID: 31547836
[TBL] [Abstract][Full Text] [Related]
5. Role of the microenvironment in hepatocellular carcinoma development and progression.
Wu SD; Ma YS; Fang Y; Liu LL; Fu D; Shen XZ
Cancer Treat Rev; 2012 May; 38(3):218-25. PubMed ID: 21763074
[TBL] [Abstract][Full Text] [Related]
6. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma.
Coulouarn C; Clément B
J Hepatol; 2014 Jun; 60(6):1306-9. PubMed ID: 24530649
[TBL] [Abstract][Full Text] [Related]
7. Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.
Yin Z; Jiang K; Li R; Dong C; Wang L
Mol Cancer; 2018 Dec; 17(1):178. PubMed ID: 30593276
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.
Chen C; Wang Z; Ding Y; Qin Y
Front Immunol; 2023; 14():1133308. PubMed ID: 36845131
[TBL] [Abstract][Full Text] [Related]
10. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
11. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever.
Carloni V; Luong TV; Rombouts K
Liver Int; 2014 Jul; 34(6):834-43. PubMed ID: 24397349
[TBL] [Abstract][Full Text] [Related]
12. Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.
Chen Y; Zhou Y; Yan Z; Tong P; Xia Q; He K
Cell Oncol (Dordr); 2023 Dec; 46(6):1595-1604. PubMed ID: 37414962
[TBL] [Abstract][Full Text] [Related]
13. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
14. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
Akkız H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
[TBL] [Abstract][Full Text] [Related]
15. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
[TBL] [Abstract][Full Text] [Related]
16. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma.
Shen C; Li M; Duan Y; Jiang X; Hou X; Xue F; Zhang Y; Luo Y
Front Immunol; 2023; 14():1170207. PubMed ID: 37304265
[TBL] [Abstract][Full Text] [Related]
18. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment.
Manka P; Coombes JD; Boosman R; Gauthier K; Papa S; Syn WK
Cancer Lett; 2018 Apr; 419():175-186. PubMed ID: 29414304
[TBL] [Abstract][Full Text] [Related]
20. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.
Liu YC; Yeh CT; Lin KH
Cells; 2020 May; 9(6):. PubMed ID: 32466488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
